For research use only. Not for use in humans.

Sasanlimab (Anti-PDCD1 / PD-1 / CD279)

Synonyms: PF-06801591 Cat.No.A3038

Sasanlimab (Anti-PDCD1 / PD-1 / CD279) is a monoclonal antibody targeting programmed cell death protein 1 (anti-PD-1). It has potential antineoplastic activities and can be used in the treatment of advanced or metastatic non-small-cell lung cancer and urothelial carcinoma. MW :146.46 KD.

Quality Control

Cited in Nature Medicine for its top-tier quality
SDS
Datasheet

Specificity

Name	Citation	PD-1/PD-L1 interaction	PD-1	PD-L1	PD-1/PD-L1	Others
GS-4224	0	++++			++++
INCB086550	1	++			++
BMS-1001	0	+			+
BMS-1166	8	+++
PD-1/PD-L1 Inhibitor 3	13	+++
BMS-1	13	++
BMS202	26	+
CA-170 (AUPM-170)	0			✔
SR 0987	1		✔			IL17,RORγt
Spartalizumab (anti-PD-1)	3		✔
Camrelizumab (anti-PD-1)	2		✔
AUNP-12	3			✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Sasanlimab (Anti-PDCD1 / PD-1 / CD279) is a monoclonal antibody targeting programmed cell death protein 1 (anti-PD-1). It has potential antineoplastic activities and can be used in the treatment of advanced or metastatic non-small-cell lung cancer and urothelial carcinoma. MW :146.46 KD.
References	[1] https://pubmed.ncbi.nlm.nih.gov/37385154/

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	2206792-50-7
Isotype	Human IgG4SP
Source	CHO
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.